Organovo Holdings, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own1.81% Shs Outstand8.71M Perf Week-11.61%
Market Cap23.22M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float8.55M Perf Month-22.37%
Income-12.10M PEG- EPS next Q- Inst Own17.90% Short Float3.67% Perf Quarter-18.06%
Sales- P/S- EPS this Y15.60% Inst Trans-11.90% Short Ratio9.82 Perf Half Y-50.21%
Book/sh3.59 P/B0.66 EPS next Y- ROA-32.50% Target Price- Perf Year-66.71%
Cash/sh3.08 P/C0.77 EPS next 5Y- ROE-34.20% 52W Range2.24 - 11.25 Perf YTD-34.99%
Dividend- P/FCF- EPS past 5Y22.20% ROI- 52W High-79.02% Beta0.60
Dividend %- Quick Ratio15.50 Sales past 5Y- Gross Margin- 52W Low5.36% ATR0.20
Employees7 Current Ratio15.50 Sales Q/Q- Oper. Margin- RSI (14)34.57 Volatility7.45% 7.73%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.80% Profit Margin- Rel Volume0.29 Prev Close2.42
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume31.93K Price2.36
Recom3.00 SMA20-10.84% SMA50-25.79% SMA200-49.74% Volume9,305 Change-2.60%
Dec-13-18Initiated H.C. Wainwright Buy $2.50
Nov-10-17Downgrade Raymond James Outperform → Mkt Perform
Jan-25-17Initiated Raymond James Outperform
Aug-11-15Downgrade Cantor Fitzgerald Buy → Hold
Jun-29-15Initiated Piper Jaffray Overweight $5
Jun-29-15Initiated Jefferies Buy $5
May-17-22 08:05AM  
Mar-03-22 10:13PM  
Mar-01-22 08:05AM  
Feb-23-22 08:05AM  
Feb-18-22 04:00PM  
Feb-12-22 02:09PM  
Feb-04-22 10:11AM  
Feb-02-22 12:00PM  
Jan-21-22 11:37AM  
Jan-10-22 12:00PM  
Dec-30-21 09:24AM  
Nov-30-21 08:05AM  
Sep-17-21 04:10PM  
Jun-22-21 10:17AM  
Jun-15-21 11:38AM  
Mar-02-21 08:05AM  
Feb-07-21 09:19AM  
Sep-03-20 04:05PM  
Aug-17-20 08:05AM  
Jun-10-20 03:43PM  
Apr-08-20 10:32AM  
Apr-07-20 04:12PM  
Apr-02-20 08:00AM  
Mar-31-20 06:30PM  
Mar-28-20 02:27PM  
Mar-27-20 04:05PM  
Mar-23-20 03:30PM  
Mar-19-20 02:36PM  
Feb-26-20 08:30AM  
Jan-21-20 07:00AM  
Jan-07-20 08:00AM  
Dec-17-19 07:03PM  
Dec-16-19 07:00AM  
Nov-21-19 07:19AM  
Nov-18-19 09:18AM  
Nov-15-19 07:06AM  
Nov-07-19 10:30AM  
Oct-03-19 07:34AM  
Oct-02-19 07:31PM  
Sep-11-19 01:29PM  
Sep-06-19 09:36AM  
Aug-08-19 08:50PM  
Aug-07-19 09:00AM  
Aug-01-19 10:32AM  
Jul-18-19 08:05AM  
Jul-09-19 02:59PM  
Jul-08-19 08:05AM  
Jun-26-19 06:57AM  
Jun-25-19 08:37AM  
Jun-13-19 08:05AM  
Jun-10-19 12:36PM  
Jun-05-19 01:16AM  
May-30-19 08:05AM  
May-24-19 07:44AM  
May-22-19 04:05PM  
May-17-19 08:05AM  
Apr-26-19 01:01PM  
Apr-17-19 08:05AM  
Mar-14-19 08:05AM  
Feb-20-19 08:05AM  
Feb-13-19 03:29AM  
Feb-12-19 07:45AM  
Feb-08-19 02:35PM  
Feb-07-19 06:40PM  
Jan-31-19 10:31AM  
Jan-22-19 10:57AM  
Jan-17-19 08:05AM  
Dec-06-18 08:05AM  
Dec-04-18 06:19PM  
Nov-12-18 08:05AM  
Nov-08-18 07:30PM  
Oct-18-18 08:05AM  
Oct-17-18 07:30AM  
Oct-15-18 08:05AM  
Sep-26-18 08:05AM  
Sep-19-18 02:27PM  
Aug-27-18 03:50PM  
Aug-14-18 08:15PM  
Aug-10-18 07:38AM  
Aug-09-18 07:20PM  
Aug-01-18 08:05AM  
Jul-20-18 07:25AM  
Jul-19-18 08:05AM  
Jun-05-18 12:03PM  
Jun-01-18 03:04PM  
May-31-18 04:30PM  
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cohen Douglas JayDirectorAug 17Buy6.732,00013,4581,000Aug 19 04:05 PM
Cohen Douglas JayDirectorAug 17Buy6.728,75058,83810,000Aug 19 04:05 PM